Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sc-41390 SCHEMBL29369604 | 0.95 | LTB4R (1.00) | LTB4RLTB4R2 | |
| Sc-41390 SCHEMBL1889110 | 0.95 | LTB4R (1.00) | LTB4RLTB4R2 | |
| Sc-41390 SCHEMBL29403478 | 0.95 | LTB4R (1.00) | LTB4RLTB4R2 | |
| Sc-41390 SCHEMBL6372085 | 0.94 | LTB4R (0.98) | LTB4RLTB4R2 | |
| SCHEMBL8941423 | 0.92 | LTB4R (0.90) | LTB4RLTB4R2 | |
| SCHEMBL9198703 | 0.92 | LTB4R (0.77) | LTB4RLTB4R2 | |
| SCHEMBL5694768 | 0.92 | LTB4R (0.95) | LTB4RLTB4R2 | |
| SCHEMBL8941563 | 0.91 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL9526565 | 0.91 | LTB4R (0.88) | LTB4RLTB4R2 | |
| SCHEMBL9821725 | 0.90 | LTB4R (0.87) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0292977-B1 | ALKOXY-SUBSTITUTED DIHYDROBENZOPYRAN-2-CARBOXYLATE DERIVATIVES | G.D. Searle & Co. (US) | 1991-09-04 | — | — | EP | claimed |
| US-4889871-A | ANTIINFLAMMATORY AGENTS; SELECTIVE LEUKOTRIENE ANTAGONISTS | G. D. SEARLE & CO. (US) | 1989-12-26 | — | — | US | claimed |
| EP-0292977-A1 | Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives | G.D. Searle & Co. (US) | 1988-11-30 | — | — | EP | claimed |
| JP-1038045-A | — | — | None | — | — | JP | disclosed |
| EP-1115397-B1 | COMPOSITIONS FOR MITIGATING THE ADVERSE EFFECTS OF INTERLEUKIN-2 | INTARCIA THERAPEUTICS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1115397-A4 | METHOD OF MITIGATING THE ADVERSE EFFECTS OF INTERLEUKIN-2 | BIOMEDICINES INC (US) | 2003-08-06 | — | — | EP | disclosed |
| US-6423744-B2 | ADMINISTERING AN AMOUNT OF A LEUKOTRIENE B4 (LTB4) ANTAGONIST, PREFERABLY A LTB4 RECEPTOR ANTAGONISTIC, TO A PATIENT EXHIBITING ADVERSE DRUG EFFECT DUE TO EXOGENOUS INTERLEUKIN-2, TO DECREASE THE ADVERSE EFFECTS | BIOMEDICINES, INC. | 2002-07-23 | — | — | US | disclosed |
| US-20020016360-A1 | Method of diminishing the adverse effects of interleukin-2 | INTARCIA THERAPEUTICS, INCORPORATED | 2002-02-07 | — | — | US | disclosed |
| EP-1115397-A1 | METHOD OF MITIGATING THE ADVERSE EFFECTS OF INTERLEUKIN-2 | Biomedicines, Inc. (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000012086-A1 | METHOD OF MITIGATING THE ADVERSE EFFECTS OF INTERLEUKIN-2 | BIOMEDICINES, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
| EP-0292977-B1 | ALKOXY-SUBSTITUTED DIHYDROBENZOPYRAN-2-CARBOXYLATE DERIVATIVES | G.D. Searle & Co. (US) | 1991-09-04 | — | — | EP | disclosed |
| US-4889871-A | ANTIINFLAMMATORY AGENTS; SELECTIVE LEUKOTRIENE ANTAGONISTS | G. D. SEARLE & CO. (US) | 1989-12-26 | — | — | US | disclosed |
| EP-0292977-A1 | Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives | G.D. Searle & Co. (US) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016360-A1 | Method of diminishing the adverse effects of interleukin-2 | LTB4R2, IL2, LTB4R | LTB4R 3/4885LTB4R2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.